# Injectable Peptide Stacks and Human Recovery

CJC-1295 and ipamorelin can stimulate GH, but the marketed combination has no verified human physical-recovery benefit in this bounded review.

The preregistered primary-subclaim rule returns SC2 Γ: mechanistic plausibility and partial system support are present, but an exact-combination positive clinical recovery experiment is missing. This is an unproven benefit claim, not a claim that every peptide is ineffective or that future recovery benefit is impossible. Fifty-plus examined originals are mostly component, mechanism, comparator and indication-boundary reports, not fifty trials of the marketed combination.

Direct clinical generalization of the exact combination has not been tested in the examined corpus. These neighboring boundaries constrain analogy; they do not constitute a mapped efficacy boundary for a successful exact-stack trial.